Twinbeech Capital LP Chemo Centryx, Inc. Transaction History

Twinbeech Capital LP

  • $4.99 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
BUY
$15.36 - $27.51 $163,783 - $293,339
10,663 New
10,663 $264,000
Q1 2021

May 17, 2021
SELL
$49.53 - $68.4 $168,154 - $232,218
-3,395 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$47.25 - $65.16 $160,413 - $221,218
3,395 New
3,395 $210,000
Q2 2020

Aug 14, 2020
SELL
$38.58 - $65.07 $428,932 - $723,448
-11,118 Closed
0 $0
Q1 2020

May 15, 2020
BUY
$32.73 - $50.78 $363,892 - $564,572
11,118 New
11,118 $447,000

Others Institutions Holding CCXI

# of Institutions
6
Shares Held
66.3K
Call Options Held
0
Put Options Held
0
View Full List

About ChemoCentryx, Inc.

CCXI Quotes by TradingView
  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Twinbeech Capital LP Portfolio

Follow Twinbeech Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Twinbeech Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email